Thank you Mycroft for your input it's really appreciated especially knowing now you actually have met Dr Fadiran ! Im holding as well and averaging down too.
Nothing has changed about the scientific offering of Anavex. In fact, I am a bigger a fan of the scientific offering than ever before and have gratefully added more stock in the 3’s. If the market gods should be so benevolent… I will do another very large buy in the 2’s and drop my break-even to a level I never thought possible.
I follow the science and the science says to hold the line. And so hold the line I shall… and hold it…with vigor.
Be certain, these thoughts and perspectives are shared.
I got a bunch of shares around $3.00, too; will be taking on new AVXLs if or when the share price dips below $3.
If that never happens and the share price begins a strong, info-based ascent, I'll chase it, probably with a few Jan 2019 call positions.
The science is strong, unabated. A matter of time. With Anavex, persistent patience powers profit potently.
Thanks for weighing-in your thoughts. I am NOT a seasoned bio-tech investor and watching the bleed-down of the SP the past 4 months, I did have a bit of concern = no trials starts in 2017. It sure has been a roller-coaster of a ride investing in Anavex but NO RISK = NO REWARD. So:
"And so hold the line I shall… and hold it…with vigor"
Have a safe and Merry Christmas my friend!
-Fireman
PS. Could you give us your thoughts about the PD trial now taking place in Europe? Some here speculate the FDA did not think Anavex has enough resources to run 2 trials concurrent to each other. Just curious as to what you think of situation. Also, do you have any idea of how long it may take the EU to approve trial design/endpoints?
Mycroft: We have not heard from you in quite awhile. I am sure your still out here somewhere. I would your take on this "Right to Try" Legislation and how this may effect Anavex and its lead compound Anave 2-73. Maybe it wont effect Anavex at all? Your insight/thoughts is always appreciated.